E7P Stock Chart & Stats
€30.20
--
Market closed
€30.20
--
Day’s Range― - ―
52-Week Range€19.60 - €36.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.00
Market Cap
€3.80B
Enterprise Value€5.37B
Total Cash (Recent Filing)€222.00M
Total Debt (Recent Filing)€509.00M
Price to Earnings (P/E)12.5
Beta0.01
Next Earnings
Oct 29, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.84
Shares Outstanding118,031,940
10 Day Avg. Volume6
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-47.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.61Price Target Upside34.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)3.5
Revenue Forecast (FY)€1.13B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE IP And Market PositionLong-dated patent protection and manufacturing complexity can preserve SUBLOCADE’s commercial differentiation and reduce near-term generic pressure. This supports pricing power, sustained physician and payer adoption, and a durable foundation for investment in the company’s largest growth product.
Revenue And Profitability ReboundThe latest reported growth combines stronger revenue with materially improved profitability, indicating better operating leverage rather than growth without earnings support. If sustained, this trajectory can strengthen internal funding capacity, improve resilience, and support continued commercial investment.
Merger Scale And Cost SynergiesThe Supernus combination would broaden Indivior’s CNS portfolio and create greater commercial and operating scale. Identified cost synergies provide a concrete route to efficiency gains within 12 months, while a diversified set of marketed medicines could support more durable growth.
Bears Say
Weak Cash Conversion And Negative EquityNegative operating and free cash flow despite positive TTM net income points to uneven earnings conversion and reduced self-funding capacity. Combined with a persistent equity deficit, this can limit financial flexibility and make the business more exposed when operating conditions or investment needs deteriorate.
SUBLOCADE Revenue ConcentrationReliance on one product for nearly half of pro forma revenue increases the company’s exposure to changes in adoption, reimbursement, competition, or product performance. A slowdown in SUBLOCADE would therefore have an outsized effect on consolidated growth and the merged group’s earnings profile.
Merger Execution And Synergy UncertaintyThe transaction’s benefits depend on completing integration, preserving commercial momentum, and realizing planned efficiencies across two organizations. Because revenue synergies have not been quantified and closing approvals remain outstanding, the strategic upside carries meaningful execution and timing uncertainty.
Indivior News
E7P FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was €19.60 and its highest was €36.20 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is €3.80B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Oct 29, 2026 which is in 15 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Aug 03, 2026. The company reported €0.997 earnings per share for the quarter, beating the consensus estimate of €0.753 by €0.244.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.92.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 118,031,940 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of €0.997 in its last earnings report, beating expectations of €0.753. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in DE:E7P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.61 (34.47% Upside)
€40.61 (34.47% Upside)
Blogger Sentiment
Bullish
DE:E7P Sentiment 86%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth €96.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.38%
12-Months-Change
Fundamentals
Return on Equity
-216.13%
Trailing 12-Months
Asset Growth
-15.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
E7P Company Deck
E7P Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and optimistic view of the merger: management emphasized scale, a diversified portfolio (~$2.2B pro forma revenue), strong pro forma profitability (adjusted EBITDA $888M; ~41% margin), and $125M of near-term cost synergies, while retaining balance sheet strength and highlighting SUBLOCADE as a durable, large growth driver (~44% of revenue) supported by IP and commercial momentum. Noted risks include revenue concentration in SUBLOCADE, increased pro forma net debt (~$878M, ~1x leverage), absence of quantified revenue synergies, and standard integration and regulatory execution risks. On balance, the positives (scale, margins, synergies, product durability) outweigh the lowlights.View all DE:E7P earnings summariesE7P Stock 12 Month Forecast
Average Price Target
€40.61
▲(34.47% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―